


Clean Copy of Allowed Claims 2-26

2. A compound of formula (II):



or a pharmaceutically acceptable salt thereof,
wherein

the α -nitrogen of AA^1 , AA^2 , AA^3 , AA^4 , AA^5 , AA^6 , AA^7 , and AA^8 each is, independently, optionally substituted with (C_{1-4})alkyl, (C_{3-4})alkenyl, (C_{3-4})alkynyl, or (C_{1-6})alkyl-C(O)-;
 AA^1 is absent or the D- or L-isomer of an amino acid selected from the group consisting of R^{11} , Aac, Aic, Arg, Asn, Asp, Dip, Gln, Glu, Hyp, Lys, Mac, Macab, Orn, Pip, Pro, Ser, Ser(Bzl), Thr, Thr(Bzl), Pip, hArg, Bip, Bpa, Tic, Cmp, Inc, Inp, Nip, Ppc, Htic, Thi, Tra, Cmpi, Tpr, [,] Iia, Alla, Aba, Gba, Car, Ipa, Iaa, Inip, Apa, Mim, Thnc, Sala, Aala, Thza, Thia, Bal, Fala, Pala, Dap, Agly, Pgly, Ina, Dipa, Mnf, Inic, I-Iqc, 3-Iqc, C4c, 5-Iqs, Htqa, 4-Mqc, Thn, α -Chpa, Cit, Nua, Pyp and an optionally substituted aromatic α -amino acid,

wherein said optionally substituted aromatic α -amino acid is optionally substituted with one or more substituents selected from the group consisting of halogen, NO_2 , OH , CN , (C_{1-6})alkyl, (C_{2-6})alkenyl, (C_{2-6})alkynyl, and NR^9R^{10} ;
 AA^2 is absent or the D- or L-isomer of an amino acid selected from the group consisting of R^{11} , Aic, Arg, Hca, His, Hyp, Pal, F_5 -Phe, Phe, Pro, Trp, X^0 -Phe, Pip, hArg, Bip, Bpa, Tic, Cmp, Inc, Inp, Nip, Ppc, Htic, Thi, Tra, Cmpi, Tpr, Iia, Alla, Aba, Gba, Car, Ipa, Iaa, Inip, Apa, Mim, Thnc, Sala, Aala, Thza, Thia, Bal, Fala, Pala, Dap,

Agly, Pgly, Ina, Dipa, Mnf, Inic, I-Iqc, 3-Iqc, C4c, 5-Iqs, Htqa, 4-Mqc, Thn, α -Chpa, Cit, Nua, and Pyp; AA³ is the D- or L-isomer of an amino acid selected from the group consisting of Cys, hCys, Pen, Tpa and Tmpa;

AA⁴ is a D- or L-isomer of an amino acid selected from the group consisting of Trp, N-Met-Trp, β -Met-Trp, His, hHis, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, Pala, and an optionally substituted aromatic α -amino acid,

wherein said optionally substituted aromatic α -amino acid is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, NO₂, OH, (C₁₋₄)alkyl, (C₂₋₄)alkenyl, (C₂₋₄)alkynyl, Bzl, O-Bzl, and NR⁹R¹⁰;

AA⁵ is a D- or L-isomer of an amino acid selected from the group consisting of 4-Pip-Gly, 4-Pip-Ala, *cis*-4-Acha, *trans*-4-Acha, *trans*-4-Amcha, hLys, Lys, Orn, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, and Pala,

wherein the side-chain amino group of said amino acid is optionally mono- or di-substituted with R³ and R⁴;

AA⁶ is a D- or L-isomer of an amino acid selected from the group consisting of Cys, hCys, Pen, Tpa, and Tmpa;

AA⁷ is absent or a D- or L-isomer of an amino acid selected from the group consisting of R¹¹, Aic, A3c, A4c, A5c, A6c, Abu, Aib, β -Ala, Arg, Bpa, Cha, Deg, Gaba, His, Ile, Leu, Nal, Nle, Pal, Phe, F₅-Phe, Pro, Sar, Ser, Ser(Bzl), Thr, Thr(Bzl), Trp, N-Me-Trp, Val, N-Me-Val, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, Pala, and X⁰-Phe;

AA⁸ is absent or the D- or L-isomer of an amino acid selected from the group consisting of R¹¹, an optionally substituted aromatic α -amino acid, Maa, Maaab, Ser, Ser(Bzl), Thr, Thr(Bzl), Tyr, Phe(4-O-Bzl), F₅-Phe, and X⁵-Phe;

R¹ and R² each is, independently, H, E-, E(O)₂S-, E(O)C-, EOOC-, R¹³, or absent;




R³ and R⁴ each is, independently, (C₁₋₁₂)alkyl, (C₂₋₁₂)alkenyl, (C₂₋₁₂)alkynyl, phenyl, naphthyl, phenyl-(C₁₋₆)alkyl, phenyl-(C₂₋₆)alkenyl, phenyl-(C₂₋₆)alkynyl, naphthyl-(C₁₋₆)alkyl, naphthyl-(C₂₋₆)alkenyl, naphthyl-(C₂₋₆)alkynyl, (cyclo(C₃₋₇)alkyl)-(C₁₋₆)alkyl, (cyclo(C₃₋₇)alkyl)-(C₂₋₆)alkenyl, (cyclo(C₃₋₇)alkyl)-(C₂₋₆)alkynyl, heterocyclyl-(C₁₋₄)alkyl, heterocyclyl-(C₂₋₄)alkenyl, heterocyclyl-(C₂₋₄)alkynyl, 1-adamantyl, 2-adamantyl, 9-fluorenylmethyl, dicyclopropylmethyl, dimethylcyclopropylmethyl, or benzhydryl;

R⁵ is -OR⁶, -NR⁷R⁸, or absent,

wherein each R⁶, R⁷ and R⁸ is, independently, H, (C₁₋₁₂)alkyl, (C₂₋₁₂)alkenyl, (C₂₋₁₂)alkynyl, phenyl, naphthyl, phenyl-(C₁₋₆)alkyl, phenyl-(C₂₋₆)alkenyl, phenyl-(C₂₋₆)alkynyl, naphthyl-(C₁₋₆)alkyl, naphthyl-(C₂₋₆)alkenyl, naphthyl-(C₂₋₆)alkynyl, 1-adamantyl, 2-adamantyl, 9-fluorenylmethyl, dicyclopropylmethyl, dimethylcyclopropylmethyl, or benzhydryl;


R⁹ and R¹⁰ each is, independently, H, (C₁₋₆)alkyl, (C₃₋₄)alkenyl, (C₃₋₄)alkynyl, 1-adamantyl, or 2-adamantyl;

R¹¹ is, independently for each occurrence, a D- or L-amino acid of the formula:




wherein m and n each is, independently, 1, 2, or 3, and p is 0, 1, or 2;

R^{12} is, independently for each occurrence, an optionally substituted moiety of the formula:



R^{13} is a moiety according to the formula



wherein R^{21} is (C_{1-4}) alkyl and s is 1, 2, 3, or 4;

E is, independently for each occurrence, an optionally substituted moiety selected from the group consisting of (C_{1-12}) alkyl, (C_{2-12}) alkenyl, (C_{2-12}) alkynyl, phenyl, naphthyl, phenyl- (C_{1-6}) alkyl, phenyl- (C_{2-6}) alkenyl, phenyl- (C_{2-6}) alkynyl, naphthyl- (C_{1-6}) alkyl, naphthyl- (C_{2-6}) alkenyl, naphthyl- (C_{2-6}) alkynyl, $(\text{cyclo}(\text{C}_3\text{-}7)\text{alkyl})-(C_{1-6})\text{alkyl}$, $(\text{cyclo}(\text{C}_3\text{-}7)\text{alkyl})-(C_{2-6})\text{alkenyl}$, $(\text{cyclo}(\text{C}_3\text{-}7)\text{alkyl})-(C_{2-6})\text{alkynyl}$, heterocyclyl- $(C_{1-4})\text{alkyl}$, heterocyclyl- $(C_{2-4})\text{alkenyl}$, heterocyclyl- $(C_{2-4})\text{alkynyl}$, 1-adamantyl, 2-adamantyl, dicyclopropylmethyl, dimethylcyclopropylmethyl, 9-fluorenylmethyl, and benzhydryl;

wherein the optionally substituted moiety defined for E is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, OH, Bzl, O-Bzl, NO₂, CN, COOH, and SH;

X^0 is halogen, NO_2 , CH_3 , OH , BzI , O-BzI or CN ;

X^1 is H , $(\text{C}_{1-6})\text{alkyl}$, $(\text{C}_{2-6})\text{alkenyl}$, $(\text{C}_{2-6})\text{alkynyl}$, indolyl, imidazolyl, 1-naphthyl, 3-pyridyl, optionally ring-substituted benzyl, or a moiety which corresponds to the side-chain group of Arg, Leu, Gln, Lys, Tyr, His, Thr, Trp, Phe, Val, Ala, Lys, or His;

wherein said optionally ring-substituted benzyl is optionally substituted with one or more substituents selected from the group consisting of halogen, OH , $(\text{C}_{1-6})\text{alkoxy}$, mono- or di- $(\text{C}_{1-6})\text{alkylamino}$, $(\text{C}_{1-4})\text{alkyl}$, $(\text{C}_{2-4})\text{alkenyl}$, $(\text{C}_{2-4})\text{alkynyl}$, and NR^9R^{10} ;

X^2 and X^3 each is, independently, H , halogen, OH , $=\text{O}$, $=\text{S}$, $(\text{C}_{1-12})\text{alkyl}$, $(\text{C}_{2-12})\text{alkenyl}$, $(\text{C}_{2-12})\text{alkynyl}$, phenyl, naphthyl, phenyl- $(\text{C}_{1-6})\text{alkyl}$, phenyl- $(\text{C}_{2-6})\text{alkenyl}$, phenyl- $(\text{C}_{2-6})\text{alkynyl}$, naphthyl- $(\text{C}_{1-6})\text{alkyl}$, naphthyl- $(\text{C}_{2-6})\text{alkenyl}$, naphthyl- $(\text{C}_{2-6})\text{alkynyl}$, $(\text{cyclo}(\text{C}_{3-7})\text{alkyl})-(\text{C}_{1-6})\text{alkyl}$, $(\text{cyclo}(\text{C}_{3-7})\text{alkyl})-(\text{C}_{2-6})\text{alkenyl}$, $(\text{cyclo}(\text{C}_{3-7})\text{alkyl})-(\text{C}_{2-6})\text{alkynyl}$, heterocyclyl- $(\text{C}_{1-4})\text{alkyl}$, heterocyclyl- $(\text{C}_{2-4})\text{alkenyl}$, heterocyclyl- $(\text{C}_{2-4})\text{alkynyl}$, 1-adamantyl, 2-adamantyl, dicyclopropylmethyl, or dimethylcyclopropylmethyl;

X^4 is H , OH , or NH_2 ; and

X^5 is halogen, NO_2 , CH_3 , OH , BzI or O-BzI ;

provided that:

at least one of AA^7 or AA^8 is present;

at least six amino acid residues are present;

when AA^1 is a D- or L-isomer of an amino acid selected from the group consisting of Mac or Macab, then AA^8 is a D- or L-isomer of an amino acid selected from the group consisting of Maa and Maaab, and when AA^8 is a D- or L-isomer of an amino acid selected from the group

consisting of Maa and Maaab, then AA¹ is a D- or L-isomer of Mac or of Macab, and AA¹ is connected by a disulfide bond with AA⁸;

AA² can be D- or L-Hca only when AA¹ is absent; when one of R¹ or R² is E(O)₂S-, E(O)C-, EOOC-, or R¹³, the other is H;

when R⁵ is absent, then one of R¹ or R² is also absent, and the N-terminal amino acid and C-terminal amino acid together form an amide bond;


when one of X² or X³ is C=O or C=S, the other is absent; and

said compound of formula (I) is not of the formula:

D-4-NO₂-Phe-Phe(4-O-Bzl)-cyclo(D-Cys-D-Trp-Lys-Cys)Cham-Nal-NH₂; or

D-4-NO₂-Phe-cyclo(D-Cys-Phe(4-O-Bzl)-D-Trp-Lys-Cys)-Val-Tyr-NH₂.

3. A compound of formula (III):



or a pharmaceutically acceptable salt thereof,

wherein

AA¹ is absent or the D- or L-isomer of an amino acid selected from the group consisting of R¹¹, Aac, Aic, Arg, Asn, Asp, Gln, Glu, Hca, His, Hyp, Lys, Mac, Macab, Orn, Pro, Ser, Ser(Bzl), Thr, Thr(Bzl), Pip, hArg, Bip, Bpa, Tic, Cmp, Inc, Inp, Nip, Ppc, Htic, Thi, Tra, Cmpi, Tpr, Iia, Alla, Aba, Gba, Car, Ipa, Iaa, Inip, Apa, Mim, Thnc, Sala, Aala, Thza, Thia, Bal, Fala, Pala, Dap, Agly, Pgly, Ina, Dipa, Mnf, Inic, I-Iqc, 3-Iqc, C4c, 5-Iqs, Htqa, 4-

Mqc, Thn, α -Chpa, Cit, Nua, Pyp and an optionally substituted aromatic α -amino acid,

wherein said optionally substituted aromatic α -amino acid is optionally substituted with one or more substituents selected from the group consisting of halogen, NO₂, OH, CN, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, and NR⁹R¹⁰;

AA³ is a D- or L-isomer of an amino acid selected from the group consisting of Cys, hCys, Pen, Tpa, and Tmpa;

AA^{3b} is the D- or L-isomer of an amino acid selected from the group consisting of R¹¹, Arg, Bpa, F₅-Phe, His, Nal, Pal, 4-Pal, Phe, Trp, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, Pala, and X⁵-Phe;

AA⁴ is a D- or L-isomer of an amino acid selected from the group consisting of Trp, N-Met-Trp, β -Met-Trp, His, hHis, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, Pala, and an optionally substituted aromatic α -amino acid;

wherein said optionally substituted aromatic α -amino acid is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, NO₂, OH, CN, (C₁₋₄)alkyl, (C₂₋₄)alkenyl, (C₂₋₄)alkynyl, Bzl, O-Bzl, and NR⁹R¹⁰;

AA⁵ is a D- or L-isomer of an amino acid selected from the group consisting of 4-Pip-Gly, 4-Pip-Ala, cis-4-Acha, trans-4-Acha, trans-4-Amcha, hLys, Lys, and Orn, and, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, and Pala,

wherein the side-chain amino group of said amino acid is optionally mono- or di-substituted with R³ and R⁴;

AA⁶ is a D- or L-isomer of an amino acid selected from the group consisting of Cys, hCys, Pen, Tpa, and Tmpa;


AA⁷ is absent or a D- or L-isomer of an amino acid selected from the group consisting of R¹¹, Aic, A3c, A4c, A5c, A6c, Abu, Aib, β -Ala, Arg, Bpa, Cha, Deg, Gaba, His, Ile, Leu, Nal, Nle, Pal, Phe, F₅-Phe, Pro, Sar, Ser, Ser(Bzl), Thr, Thr(Bzl), Trp, N-Me-Trp, Val, N-Me-Val, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, Pala, and X⁰-Phe;

X⁰ is halogen, NO₂, CH₃, OH, CN, Bzl or O-Bzl;

R¹ and R² each is, independently, H, E-, E(O)₂S-, E(O)C-, EOC-, R¹³, or absent;

R⁵ is -OR⁶ or -NR⁷R⁸;

R¹³ is a moiety of the formula



wherein R²¹ is (C₁₋₄)alkyl and s is 1, 2, 3, or 4;
provided that:

at least one of AA¹ or AA² is present;


when AA¹ is a D- or L-isomer of Pro, Hyp, Arg, Pip, hArg, Bip, Bpa, Tic, Cmp, Inc, Inp, Nip, Ppc, Htic, Thi, Tra, Cmpi, Tpr, Iia, Alla, Aba, Gba, Car, Ipa, Iaa, Inip, Apa, Mim, Thnc, Sala, Aala, Thza, Thia, Bal, Fala, Pala, Dap, Agly, Pgly, Ina, Dipa, Mnf, Inic, I-Iqc, 3-Iqc, C4c, 5-Iqs, Htqa, 4-Mqc, Thn, α -Chpa, Cit, Nua, Pyp or His, AA² cannot be a D- or L-isomer of Pro, Hyp, Arg, Pip, hArg, Bip, Bpa, Tic, Cmp, Inc, Inp, Nip, Ppc, Htic, Thi, Tra, Cmpi, Tpr, Iia, Alla, Aba, Gba, Car, Ipa, Iaa, Inip, Apa, Mim, Thnc, Sala, Aala, Thza, Thia, Bal, Fala, Pala, Dap, Agly, Pgly, Ina, Dipa, Mnf, Inic, I-Iqc, 3-Iqc, C4c, 5-Iqs, Htqa, 4-Mqc, Thn, α -Chpa, Cit, Nua, Pyp or His;

when AA⁷ is a D- or L-isomer of Thr or of Ser, AA⁸ cannot be a D- or L-isomer of Thr or of Ser;

at least one of AA¹, AA², AA^{3b}, AA⁷, AA^{7b}, or AA⁸ is the D- or L-isomer of R¹¹; and

when one of X² or X³ is =O or =S, the other is absent; or a pharmaceutically acceptable salt thereof.

4. A compound of formula (IV) :



wherein

AA¹ is absent or the D- or L-isomer of an amino acid selected from the group consisting of R¹¹, Aic, Hyp, Pro, Ser, Ser(Bzl), Thr, Thr(Bzl), Tic, Htic, Fala and an optionally substituted aromatic α -amino acid;

wherein said optionally substituted aromatic α -amino acid is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, NO₂, OH, CN, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₂₋₆)alkynyl, (C₁₋₆)alkoxy, Bzl, O-Bzl, and NR⁹R¹⁰;

AA² is absent or the D- or L-isomer of an amino acid selected from the group consisting of R¹¹, Arg, F₅-Phe, His, Pal, Phe, Trp, hArg, Pala, Bal, Fala, Sala and X⁰-Phe;

AA³ is the D- or L-isomer of an optionally substituted aromatic α -amino acid,

wherein said optionally substituted aromatic α -amino acid is optionally substituted with one or more substituents selected from the group consisting of halogen, NO₂, OH, CN, (C₁₋₄)alkyl, (C₂₋₄)alkenyl, (C₂₋₄)alkynyl, Bzl, O-Bzl, and NR⁹R¹⁰;

AA⁴ is a D- or L-isomer of an optionally substituted amino acid selected from the group consisting of Trp, N-Met-Trp,

β -Me-Trp, Lys, Orn, hLys, *cis*-4-Acha, *trans*-4-Acha, *trans*-4-Amcha, 4-Pip-Gly, 4-Pip-Ala, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, and Pala;

wherein the side chain amino group of said optionally substituted amino acid is optionally substituted with R³ and R⁴;

AA⁵ is absent or a D- or L-isomer of R¹¹, A3c, A4c, A5c, A6c, Abu, Aib, Aic, β -Ala, Bpa, Cha, Deg, F₅-Phe, Gaba, Ile, Leu, Nal, Nle, Pal, Phe, Pro, Sar, Ser, Ser(Bzl), Thr, Thr(Bzl), Trp, N-Me-Trp, Val, N-Me-Val, hArg, Bip, Tic, Htic, Dip, Sala, Aala, Thza, Thia, Bal, Fala, Pala, or X⁰-Phe;


AA⁶ is absent, the D- or L-isomer of R¹¹, an aromatic α -amino acid, F₅-Phe, Phe, Thr, Thr(Bzl), Ser, Ser(Bzl), or X⁰-Phe;

AA⁷ is absent, the D- or L-isomer of R¹¹ or the D- or L-isomer of an aromatic α -amino acid;

AA⁸ is a D- or L- isomer of R¹¹;

R¹ is H, E-, E(O)₂S-, E(O)C-, EOOC-, or R¹³;

R¹³ is a moiety of the formula



wherein R²¹ is (C₁₋₄)alkyl and s is 1, 2, 3, or 4; X⁰ in the definition of AA² and AA⁵ is halogen, NO₂, OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, mono- or di-(C₁₋₆)alkylamino, Bzl or O-Bzl;

X⁰ in the definition of AA⁶ is halogen, NO₂, OH, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, mono- or di-(C₁₋₆)alkylamino, Bzl, O-Bzl, or NR⁹R¹⁰;


provided that:

at least one of AA¹ or AA² is present;


when AA¹ is absent, AA² and AA⁸ together form a bond; and

at least two of AA⁵, AA⁶, and AA⁷ are present; or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 2, wherein AA¹ is absent, Ac-D-Phe, or the D- or L- isomer of R¹¹, Pip, Pro, or Ser, or of an aromatic α -amino acid selected from the group consisting of Cpa, Dip, Nal, Pal, and Phe;



AA² is absent, Aic, Pal, Phe, F₅-Phe, 4-NO₂-Phe, Trp, Tyr, Phe(4-O-Bzl)



AA³ is the D- or L- isomer of an amino acid selected from the group consisting of Pen, Cys, hCys and Tmpa;

AA⁴ is the D- or L-isomer of Trp, His, N-Me-Trp, β -Me-Trp, hTrp, or hHis;

AA⁵ is Lys, hLys, N-Me-Lys, Orn, cis-4-Acha or 4-Pip-Ala;

AA⁶ is the D- or L-isomer of an amino acid selected from the group consisting of Cys, hCys, Pen and Tmpa;

AA⁷ is A3c, A4c, A5c, A6c, Abu, Aic, β -Ala, Gaba, Nle, F₅-Phe, Phe, Pro, Sar, Ser, Thr, Thr(Bzl), Tyr, Val or absent; and

AA⁸ is R¹¹, Nal, Thr, Thr(Bzl), Tyr, Phe(4-O-Bzl), or absent; or a pharmaceutically acceptable salt thereof.

6. A compound according to claim 5, wherein

AA¹ is absent or the D- or L- isomer of R¹¹, Pip or Pro, or of an aromatic α -amino acid selected from the group consisting of Cpa, Dip, Nal, Pal, Phe, and Ac-Phe; AA² is Tyr, Pal, Phe, 4-NO₂-Phe, Trp, or absent; AA³ is a D- or L-isomer of Cys or Pen; AA⁴ is D-Trp; AA⁵ is Lys, Orn, or cis-4-Acha; AA⁶ is a D- or L-isomer of Cys or Pen; AA⁷ is A3c, A4c, A5c, A6c, Abu, Aic, β -Ala, Gaba, Nle, Phe, Pro, Sar, Thr, Thr(Bzl), Tyr, Val, or absent; and AA⁸ is R¹¹, Thr, Tyr, Nal, or absent; or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 3, wherein
AA¹ is R¹¹, Aic, Hca, Pro, Ser, Ser(Bzl), Trp, Tyr, or a D- or L-isomer of an aromatic α -amino acid selected from the group consisting of Cpa, Nal, Ac-Nal, Phe, Ac-Phe, 4-NO₂-Phe, and Ac-4-NO₂-Phe; AA² is Pal, Phe, F₅-Phe, Tyr, or absent; AA³ is a D- or L-isomer of Cys, hCys, Pen or Tmpa; AA^{3b} is Pal, 4-Pal, His, Trp, Tyr, Phe(4-O-Bzl), Phe, or R¹¹; AA⁴ is a D- or L-isomer of Trp or His; AA⁵ is Lys, N-Me-Lys, Orn, hLys, cis-4-Acha, or 4-Pip-Ala; AA⁶ is a D- or L-isomer of Cys, hCys, Pen or Tmpa; AA⁷ is R¹¹, A4c, A5c, Abu, β -Ala, Gaba, Phe, F₅-Phe, Ser(Bzl), Thr, Thr(Bzl), Phe(4-O-Bzl), or absent; AA^{7b} is R¹¹, Nal, F₅-Phe, X⁰-Phe or absent, wherein X⁰ is halogen, NO₂, CH₃, OH, Bzl or O-Bzl; and AA⁸ is R¹¹, Nal, Tyr, Phe(4-O-Bzl), or absent; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 7, wherein
AA¹ is R¹¹, Aic, Hca, Pro, Ser(Bzl), or a D- or L-isomer of
an aromatic α -amino acid selected from the group consisting
of Cpa, Nal, Ac-Nal, Phe, Ac-Phe, 4-NO₂-Phe, and Ac-4-NO₂-
Phe;
AA² is Pal, Tyr, or absent;
AA³ is a D- or L-isomer of Cys or Pen;
AA^{3b} is R¹¹, Pal, 4-Pal, Trp, Tyr, Phe(4-O-Bzl), or Phe,
wherein R¹¹ is (T)aeg;
AA⁴ is D-Trp;
AA⁵ is Lys, N-Me-Lys, Orn, or cis-4-Acha;
AA⁶ is a D- or L-isomer of Cys or Pen;
AA⁷ is R¹¹, A5c, Abu, Ser(Bzl), Thr, Thr(Bzl), Phe(4-O-Bzl),
Gaba, or absent;
AA^{7b} is Nal, X⁰-Phe or absent; and
AA⁸ is Tyr or absent;
or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 4, wherein
AA¹ is Aic, Hyp, Cpa, D-Cpa, Nal, Pal, Phe, Pro, R¹¹, Tyr or
absent;
AA² is Phe, Trp, F₅-Phe, His, Tyr, Phe(4-O-Bzl), or R¹¹;
AA³ is a D-isomer of Trp, His, or Pal;
AA⁴ is Lys, N-Me-Lys, Orn, hLys, cis-4-Acha, or 4-Pip-Ala;
AA⁵ is Pal, Phe(4-O-Bzl), Thr(Bzl), Thr, Sar, Gaba, β -Ala,
A4c, A5c, A6c, Abu, Aic or absent;
AA⁶ is Thr, Tyr, Ser, F₅-Phe, Cpa, Nal, or D- or L-Phe;
AA⁷ is Nal, Pal, or absent; and
AA⁸ is R¹¹;
or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 9, wherein

AA¹ is Cpa, Nal, Pal, Phe, Tyr or absent;
AA² is Phe, Tyr, Trp, or R¹¹;
AA³ is D-Trp;
AA⁴ is Lys, N-Me-Lys, or cis-4-Acha;
AA⁵ is Pal, Phe(4-O-Bzl), Aic, Gaba, A5c or absent;
AA⁶ is Thr, Nal, or D- or L-Phe;
AA⁷ is absent; and
AA⁸ is R¹¹;
or a pharmaceutically acceptable salt thereof.

11. A compound according to claim 2, wherein R¹ and R⁵ are absent and the N-terminal amino acid and the C-terminal amino acid together form an amide bond; or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 3, wherein R¹ and R⁵ are absent and the N-terminal amino acid and the C-terminal amino acid together form an amide bond; or a pharmaceutically acceptable salt thereof.

13. A compound according to claim 6, wherein said compound is of the formula:

Ac-D-Phe-Tyr-cyclo(D-Cys-D-Trp-Lys-Cys)-Abu-Thr-NH₂;
Nal-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Nal-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
D-Dip-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Dip-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Dip-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
cyclo(D-Phe-Tyr-cyclo(D-Cys-D-Trp-Lys-Cys)-Abu-Thr);
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A3c-Nal-NH₂;

Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A6c-Nal-NH₂;
(G(z))aeg-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)- β -Ala-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Sar-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Pro-Nal-NH₂;
Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Nle-Phe-NH₂;
Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Thr-Nle-NH₂;
Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Thr-Phe-NH₂;
Cpa-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Gaba-NH₂;
Cpa-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Tyr-NH₂;
Pip-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-NH₂;
Pip-Phe-c(Cys-D-Trp-Lys-Cys)-Gaba-NH₂; or
Pro-Phe-c(D-Cys-D-Trp-Lys-D-Cys)-Thr-NH₂;
or a pharmaceutically acceptable salt thereof.

14. A compound according to claim 6, wherein said compound is according to the formula:

Phe-cyclo(Cys-D-Trp-Lys-Cys)-Thr-NH₂;
Phe-Tyr-cyclo(D-Cys-D-Trp-Lys-Cys)-Abu-Thr-NH₂;
Ac-D-Phe-Tyr-cyclo(D-Cys-D-Trp-Lys-Cys)-Abu-Thr-NH₂;
Nal-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Nal-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Dip-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Dip-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A3c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A6c-Nal-NH₂;

(G(z))aeg-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
D-Cpa-cyclo(Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)- β -Ala-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Sar-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Aic-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Pro-Nal-NH₂;
(T)aeg-cyclo(D-Cys-D-Trp-Lys-D-Cys)-(A)aeg-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A4c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Nal-NH₂;
Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Nal-NH₂;
Pro-Phe-cyclo(Cys-D-Trp-Lys-D-Cys)-Val-NH₂;
Pro-Phe-cyclo(D-Cys-D-Trp-Lys-Cys)-Val-NH₂;
Pip-4-NO₂-Phe-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Nle-NH₂;
(G)aeg-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Thr(Bzl)-
(C)aeg-NH₂; or
(C)aeg-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Thr(Bzl)-
(G)aeg-NH₂;
or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 8, wherein said compound is according to the formula

Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Cys)-Thr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Ac-D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-4-NO₂-Phe-Pal-cyclo(D-Cys-Phe(4-O-Bzl)-D-Trp-Lys-Cys)-Tyr-NH₂;
Cpa-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
D-Nal-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Pro-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Cpa-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Nal-NH₂;
Ser(Bzl)-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
(A)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(G)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-4-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Phe-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Ser(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Phe(4-O-Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-A5c-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Abu-Tyr-NH₂;
D-Cpa-cyclo(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(C)aeg-c(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
D-Cpa-c(D-Cys-Pal-D-Trp-Lys-D-Cys)Thr(Bzl)-Tyr-NH₂;

(T) aeg-c (Pen-Pal-D-Trp-Lys-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Trp-D-Trp-Lys-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Phe-D-Trp-Lys-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Orn-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-hLys-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Iamp-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Cha(4-am)-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys)-Ser (Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys) Thr (Bzl)-D-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys) Thr (Bzl)-Trp-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Pen) Thr (Bzl)-Tyr-NH₂;
(C) aeg-c (D-Cys-Phe-D-Trp-Lys-D-Cys) Thr (Bzl)-Tyr-NH₂;
Ina-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr (Bzl)-Tyr-NH₂;
Mnf-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr (Bzl)-Tyr-NH₂;
Inp-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr (Bzl)-Tyr-NH₂;
Nua-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr (Bzl)-Tyr-NH₂;
(T) aeg-Pal-c (D-Cys-D-Trp-Lys-D-Cys) Thr (Bzl)-Tyr-NH₂;
(T) aeg-Pal-c (D-Cys-D-Trp-Lys-D-Cys) Tyr (Bzl)-Thr-NH₂;
(C) aeg-Phe-c (D-Cys-D-Trp-Lys-D-Cys) Thr (Bzl)-Tyr-NH₂; or
(T) aeg-D-Trp-c (D-Cys-Pal-Lys-D-Cys) Thr (Bzl)-Leu-NH₂;
or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 8, wherein said compound is according to the formula

Hca-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Ac-Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Ac-D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Ac-D-Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;

D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Cys)-Thr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Ac-D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-4-NO₂-Phe-Pal-cyclo(D-Cys-Phe(4-O-Bzl)-D-Trp-Lys-Cys)-Tyr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Cpa-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
D-Nal-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Pro-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Cpa-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Nal-NH₂;
Ser(Bzl)-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(C)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Aic-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(C(z))aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(A(z))aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
(A)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
(G)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T) aeg-cyclo (D-Cys-4-Pal-D-Trp-Lys-Cys) -Thr (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Tyr-D-Trp-Lys-Cys) -Thr (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Phe-D-Trp-Lys-Cys) -Thr (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys- (T) aeg-D-Trp-Lys-Cys) -Thr (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-Cys) -Ser (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-Cys) -Phe (4-O-Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-Cys) -A5c-Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-Cys) -Abu-Tyr-NH₂;

D-Cpa-cyclo (D-Cys- (T) aeg-D-Trp-Lys-Cys) -Thr (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-D-Cys) -Thr (Bzl) -p-Me-Phe-NH₂;

Ac- (T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-D-Cys) -Thr (Bzl) -Tyr-NH₂;

(T) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-D-Cys) -Nal-NH₂;

D-Cpa-cyclo (D-Cys-Pal-D-Trp-Lys-D-Cys) -Nal-NH₂;

(A) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-D-Cys) -Thr (Bzl) -Tyr-NH₂;

(C) aeg-cyclo (D-Cys-Pal-D-Trp-Lys-D-Cys) -Thr (Bzl) -Tyr-NH₂;

(C) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys) -Thr (Bzl) -Tyr-NH₂;

D-Cpa-c (D-Cys-Pal-D-Trp-Lys-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (Pen-Pal-D-Trp-Lys-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (D-Cys-Trp-D-Trp-Lys-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (D-Cys-Phe-D-Trp-Lys-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (D-Cys-Pal-D-Trp-Orn-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (D-Cys-Pal-D-Trp-hLys-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (D-Cys-Pal-D-Trp-Iamp-D-Cys) Thr (Bzl) -Tyr-NH₂;

(T) aeg-c (D-Cys-Pal-D-Trp-Cha(4-am)-D-Cys) Thr(Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys)-Ser(Bzl)-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys) Thr(Bzl)-D-Tyr-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Cys) Thr(Bzl)-Trp-NH₂;
(T) aeg-c (D-Cys-Pal-D-Trp-Lys-D-Pen) Thr(Bzl)-Tyr-NH₂;
(C) aeg-c (D-Cys-Phe-D-Trp-Lys-D-Cys) Thr(Bzl)-Tyr-NH₂;
Ina-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
Mnf-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
Inp-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
Nua-c (D-Cys-Phe-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;
(T) aeg-Pal-c (D-Cys-D-Trp-Lys-D-Cys) Thr(Bzl)-Tyr-NH₂;
(T) aeg-Pal-c (D-Cys-D-Trp-Lys-D-Cys) Tyr(Bzl)-Thr-NH₂;
(C) aeg-Phe-c (D-Cys-D-Trp-Lys-D-Cys) Thr(Bzl)-Tyr-NH₂; or
(T) aeg-D-Trp-c (D-Cys-Pal-Lys-D-Cys) Thr(Bzl)-Leu-NH₂;
or a pharmaceutically acceptable salt thereof.

17. A compound according to claim 10, wherein said compound is according to the formula

cyclo(Trp-D-Trp-Lys-Phe(4-O-Bzl)-Phe-(T)aeg);
cyclo(Trp-D-Trp-Lys-Pal-Phe-(T)aeg); or
cyclo(Phe-Phe-D-Trp-Lys-Thr-(T)aeg);
or a pharmaceutically acceptable salt thereof.

18. A method of eliciting a neuromedin B receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a compound according to claim 13 or a pharmaceutically acceptable salt thereof.

19. A method of eliciting a somatostatin receptor agonist effect in a subject in need thereof, wherein said

method comprises administering to said subject an effective amount of a compound according to claim 14 or a pharmaceutically acceptable salt thereof.

20. A method of eliciting a neuromedin B receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a compound according to claim 15 or a pharmaceutically acceptable salt thereof.

21. A method of eliciting a somatostatin receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a compound according to claim 16 or a pharmaceutically acceptable salt thereof.

22. A method of eliciting a somatostatin receptor agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a compound according to claim 17 or a pharmaceutically acceptable salt thereof, provided said compound is not

cyclo(Trp-D-Trp-Lys-Phe(4-O-Bzl)-Phe-(T)aeg); or

cyclo(Trp-D-Trp-Lys-Pal-Phe -(T)aeg).

23. A method of eliciting a SSTR-1 agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a compound according to claim 14 or a pharmaceutically acceptable salt thereof, provided said compound is not

Nal-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;

Nal-Tyr-cyclo(Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;

Dip-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH₂;
Dip-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Val-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A3c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A6c-Nal-NH₂;
(G(z))aeg-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
D-Cpa-cyclo(Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)- β -Ala-Nal-NH₂;
cyclo(D-Cys-D-Trp-Lys-D-Cys)-A5c-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Sar-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Aic-Nal-NH₂;
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Gaba-Nal-NH₂; or
Cpa-Pal-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Pro-Nal-NH₂.

24. A method of eliciting a SSTR-1 agonist effect in a subject in need thereof, wherein said method comprises administering to said subject an effective amount of a compound according to claim 16 or a pharmaceutically acceptable salt thereof provided said compound is not

Ac-D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Ac-D-Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-Nal-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Nal-NH₂;
D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;
Cpa-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-NH₂;

D-4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;

D-4-NO₂-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

4-NO₂-Phe-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

D-Nal-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

Pro-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

Cpa-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Nal-NH₂;

Ser(Bzl)-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(C)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

Aic-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-D-Cys)-Thr(Bzl)-Tyr-NH₂;

(A)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(G)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-4-Pal-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Tyr-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Phe-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Ser(Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Phe(4-O-Bzl)-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-A5c-Tyr-NH₂;

(T)aeg-cyclo(D-Cys-Pal-D-Trp-Lys-Cys)-Abu-Tyr-NH₂; or

D-Cpa-cyclo(D-Cys-(T)aeg-D-Trp-Lys-Cys)-Thr(Bzl)-Tyr-NH₂.

25. A pharmaceutical composition comprising an effective amount of a compound according to claim 2, 3 or 4 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to treat a medical condition or disease in a subject wherein said medical condition or disease is from the list consisting of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, *H. pylori* proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, thyroid cancer, hepatome, leukemia, meningioma, cancer cachexia, orthostatic hypotension, postprandial hypotension, panic attacks, GH secreting adenomas, TSH secreting adenomas, prolactin secreting adenomas, insulinoma, glucagonoma, diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, Nephropathy, gastric acid secretion, peptic ulcers, enterocutaneous fistula, pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, pancreatitis, gastrointestinal hormone secreting tumor, angiogenesis, arthritis, allograft rejection, graft vessel bleeding, portal hypertension, gastrointestinal bleeding, obesity, and opioid overdose.

26. A method of treating a medical condition or disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound of claim 2, 3 or 4, wherein said medical condition or disease is selected from the list consisting of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, *H. pylori* proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, VIPoma, nesidoblastosis, hyperinsulinism, gastrinoma, Zollinger-Ellison Syndrome, diarrhea, AIDS related diarrhea, chemotherapy related diarrhea, scleroderma, Irritable Bowel Syndrome, pancreatitis, small bowel obstruction, gastroesophageal reflux, duodenogastric reflux, Cushing's Syndrome, gonadotropinoma, hyperparathyroidism, Graves' Disease, diabetic neuropathy, Paget's disease, polycystic ovary disease, thyroid cancer, hepatome, leukemia, meningioma, cancer cachexia, orthostatic hypotension, postprandial hypotension, panic attacks, GH secreting adenomas, **Acromegaly**, TSH secreting adenomas, prolactin secreting adenomas, insulinoma, glucagonoma, diabetes mellitus, hyperlipidemia, insulin insensitivity, Syndrome X, angiopathy, proliferative retinopathy, dawn phenomenon, Nephropathy, gastric acid secretion, peptic ulcers, enterocutaneous fistula, pancreaticocutaneous fistula, Dumping syndrome, watery diarrhea syndrome, pancreatitis, gastrointestinal hormone secreting tumor, angiogenesis, arthritis, allograft rejection, graft vessel bleeding, portal hypertension, gastrointestinal bleeding, obesity, and opioid overdose.